EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel

Mengyan Wei, Pu Wang, Xiufang Zhu, Masaki Morishima, Yangong Liu, Mingqi Zheng, Gang Liu, Hiroki Osanai, Kenshi Yoshimura, Shinichiro Kume, Tatsuki Kurokawa, Katsushige Ono iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0280656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Mengyan Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gemcitabine is an antineoplastic drug commonly used in the treatment of several types of cancers including pancreatic cancer and non–small cell lung cancer. Although gemcitabine-induced cardiotoxicity is widely recognized, the exact mechanism of cardiac dysfunction causing arrhythmias remains unclear. The objective of this study was to electrophysiologically evaluate the proarrhythmic cardiotoxicity of gemcitabine focusing on the human rapid delayed rectifier potassium channel, hERG channel. In heterologous hERG expressing HEK293 cells (hERG-HEK cells), hERG channel current ( I hERG ) was reduced by gemcitabine when applied for 24 h but not immediately after the application. Gemcitabine modified the activation gating properties of the hERG channel toward the hyperpolarization direction, while inactivation, deactivation or reactivation gating properties were unaffected by gemcitabine. When gemcitabine was applied to hERG-HEK cells in combined with tunicamycin, an inhibitor of N-acetylglucosamine phosphotransferase, gemcitabine was unable to reduce I hERG or shift the activation properties toward the hyperpolarization direction. While a mannosidase I inhibitor kifunensine alone reduced I hERG and the reduction was even larger in combined with gemcitabine, kifunensine was without effect on I hERG when hERG-HEK cells were pretreated with gemcitabine for 24 h. In addition, gemcitabine down-regulated fluorescence intensity for hERG potassium channel protein in rat neonatal cardiomyocyte, although hERG mRNA was unchanged. Our results suggest the possible mechanism of arrhythmias caused by gemcitabine revealing a down-regulation of I hERG through the post-translational glycosylation disruption possibly at the early phase of hERG channel glycosylation in the endoplasmic reticulum that alters the electrical excitability of cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansAnimalsRatsGemcitabineERG1 Potassium ChannelDown-RegulationCardiotoxicityHEK293 CellsArrhythmias, CardiacDelayed Rectifier Potassium ChannelsEther-A-Go-Go Potassium Channels

Substanzen

GemcitabineERG1 Potassium ChannelAntineoplastic AgentsDelayed Rectifier Potassium ChannelsEther-A-Go-Go Potassium Channels

Autor:innen und Institutionen

  • Department of Cardiology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People's Republic of China.
  • Department of Pathophysiology, Oita University School of Medicine, Yufu, Oita, Japan.
  • Department of Food Science and Nutrition, Faculty of Agriculture, Kindai University, Nara, Japan.

ORCID-Profile: Katsushige Ono

Zitieren

APA

Wei, M., Wang, P., Zhu, X., Morishima, M., Liu, Y., Zheng, M., Liu, G., Osanai, H., Yoshimura, K., Kume, S., Kurokawa, T., & Ono, K. (2023). Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel. PLOS ONE. https://doi.org/10.1371/journal.pone.0280656

Vancouver

Wei M, Wang P, Zhu X, Morishima M, Liu Y, Zheng M, et al. Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel. PLOS ONE. 2023. doi:10.1371/journal.pone.0280656

BibTeX
@article{Wei2023,
  author = {Wei, Mengyan and Wang, Pu and Zhu, Xiufang and Morishima, Masaki and Liu, Yangong and Zheng, Mingqi and Liu, Gang and Osanai, Hiroki and Yoshimura, Kenshi and Kume, Shinichiro and Kurokawa, Tatsuki and Ono, Katsushige},
  title = {Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0280656}
}
Kostenlos starten →